Aptose Biosciences Inc.

Posters & Presentations

All Poster Presentation
June 12, 2025 Presentation

EHA 2025 - TUSCANY Study of Safety and Efficacy of Tuspetinib plus Standard of Care Venetoclax and Azacitidine in Study Participants with Newly Diagnosed AML Ineligible for Induction Chemotherapy

EHA 2025 - TUSCANY Study of Safety and Efficacy of Tuspetinib plus Standard of Care Venetoclax and Azacitidine in Study Participants with Newly Diagnosed AML Ineligible for Induction Chemotherapy: View Presentation
May 5, 2025 Presentation

Aptose Corporate Presentation - Bloom Burton Conference

Aptose Corporate Presentation - Bloom Burton Conference: View Presentation
March 11, 2025 Presentation

Aptose Corporate Presentation March 2025

Aptose Corporate Presentation March 2025: View Presentation
January 13, 2025 Presentation

Aptose Corporate Presentation January 2025

Aptose Corporate Presentation January 2025: View Presentation
November 7, 2024 Presentation

Aptose Corporate Presentation November 2024

Aptose Corporate Presentation November 2024: View Presentation
July 26, 2024 Presentation

Aptose Corporate Presentation July 2024

Aptose Corporate Presentation July 2024: View Presentation
May 3, 2024 Presentation

Aptose Corporate Presentation May 2024

Aptose Corporate Presentation May 2024: View Presentation
December 26, 2023 Presentation

Aptose Corporate Presentation December 2023

Aptose Corporate Presentation December 2023: View Presentation
December 9, 2023 Presentation

Tuspetinib Oral Myeloid Kinase Inhibitor Safety and Efficacy As Monotherapy and Combined with Venetoclax in Phase 1/2 Trial of Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Tuspetinib Oral Myeloid Kinase Inhibitor Safety and Efficacy As Monotherapy and Combined with Venetoclax in Phase 1/2 Trial of Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML): View Presentation